tapentadol depot g.l. pharma 150 mg depottablett
g.l. pharma gmbh - tapentadoltartrat - depottablett - 150 mg - tapentadoltartrat 251,715 mg aktiv substans
tapentadol depot g.l. pharma 250 mg depottablett
g.l. pharma gmbh - tapentadoltartrat - depottablett - 250 mg - tapentadoltartrat 419,525 mg aktiv substans
hydroxocobalamin g.l. pharma 1 mg/ml injektionsvätska, lösning
g.l. pharma gmbh - hydroxokobalaminacetat - injektionsvätska, lösning - 1 mg/ml - hydroxokobalaminacetat 1,096 mg aktiv substans
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - klopidogrelhydroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotiska medel - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
paracetamol panpharma 10 mg/ml infusionsvätska, lösning
panpharma sa - paracetamol - infusionsvätska, lösning - 10 mg/ml - glukosmonohydrat hjälpämne; paracetamol 10 mg aktiv substans - paracetamol
gentamicin panpharma 40 mg/ml injektions-/infusionsvätska, lösning
panpharma sa - gentamicinsulfat - injektions-/infusionsvätska, lösning - 40 mg/ml - gentamicinsulfat 67,8 mg aktiv substans
midazolam panpharma 1 mg/ml injektionsvätska, lösning
panpharma sa - midazolam - injektionsvätska, lösning - 1 mg/ml - midazolam 1 mg aktiv substans - midazolam
midazolam panpharma 5 mg/ml injektionsvätska, lösning
panpharma sa - midazolam - injektionsvätska, lösning - 5 mg/ml - midazolam 5 mg aktiv substans - midazolam
piperacillin/tazobactam midas pharma 4 g/0,5 g pulver till infusionsvätska, lösning
midas pharma gmbh - piperacillinnatrium; tazobaktamnatrium - pulver till infusionsvätska, lösning - 4 g/0,5 g - tazobaktamnatrium aktiv substans; piperacillinnatrium aktiv substans - piperacillin och enzymhämmare
olanzapin 1a pharma 10 mg filmdragerad tablett
1a pharma gmbh - olanzapin - filmdragerad tablett - 10 mg - olanzapin 10 mg aktiv substans; laktosmonohydrat hjälpämne - olanzapin